📰 Data Expected News
Page 2 - Data Expected News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Data Expected. Real-time updates on events, politics, business and more.
January 4, 2023
Data Expected in March 2023SAN DIEGO, CA / ACCESSWIRE / January 4, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative
October 26, 2022
/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
October 26, 2022
/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
August 4, 2022
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
May 24, 2022
24.05.2022 - - Results Showed Statistically Significant Improvement in Progression-Free Survival (PFS) Compared to Placebo (Hazard Ratio (HR) = 0.29; P
May 10, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
May 3, 2022
Topline Data Expected in 2023ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, May 3, 2022 /PRNewswire/ -- Saol Therapeutics, a privately held, clini...
January 26, 2022
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPDTop-line Data Expected in the Third Quarter of 2022 LONDON and RALEIGH, N.C., January 24, 2022 – Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”...